Chemistry: molecular biology and microbiology – Differentiated tissue or organ other than blood – per se – or... – Including perfusion; composition therefor
Patent
1994-08-26
1995-07-11
Lilling, Herbert J.
Chemistry: molecular biology and microbiology
Differentiated tissue or organ other than blood, per se, or...
Including perfusion; composition therefor
4352536, 435283, 4352402, 4352403, A01N 102
Patent
active
054320534
DESCRIPTION:
BRIEF SUMMARY
FIELD OF ART
The present invention relates to medicine and, more specifically, to a solution for conservation of living organs.
BACKGROUND OF THE INVENTION
Known in the prior art are the methods for conservation of living organs and tissues, used in medicine and involving placing said organs and tissues into special conserving solutions followed by storing them under hypothermic conditions International Meeting on Phosphocreatine in Cardiology and Cardiac Surgery, 1989, 14-15 Apr., Schiapparelli Searle (Pavia) P. Mastroberto, "Analisi degli effetti della creatina-fosfato in aggiunta a soluzione cardioplegica", p. 335-342.
Particular difficulties are encountered in conservation during surgical operations and transplantation of such an intensively functioning organ as the heart which is characterized by intensive metabolic processes and energy consumption during its contractions. If only a few years ago the surgeons were capable of protecting the heart against total ischemia by means of cardioplegia in the course of the ist hour, at present the cooling and chemical cardioplegia suggested by the Royal St. Thomas Institute and Hospital (Great Britain) ensures successful conservation of the heart for as long as 4 h. Plegisol (a commercial preparation) based on the cardioplegic solution worked out by the St. Thomas Hospital and manufactured by the Abbott Laboratories, Chicago, U.S.A., is widely used in clinical practice. Introduction of this preparation has improved cellular protection during lengthy open-heart operations, contributed to further improvement of surgical techniques and extended the period of conservation which is indispensable for heart transplantation (International Meeting on Phosphocreatine in Cardiology and Cardiac Surgery, 1989, 14-15 April. Schiapparelli Searle (Pavial) D. J. Hearse "Protection of the Ischemic Myocardium: Cardioplegia", p. 173-183.
However, the conventionally recognized time of heart conservation (4 h) is insufficient for carrying it over large distances, to any point of the globe, where it has to be transplanted to a recipient. The increased duration of conservation must be combined with improved quality and reliability of protecting the cells against ischemic and reperfusion damage.
DISCLOSURE OF THE INVENTION
The main object of the invention lies in changing the qualitative and quantitative composition of the compound in order to evolve a solution for conservation of living organs featuring a longer period of conservation and survival of cells thus ruling out their ischemic and reperfusion damage.
The object is attained by providing a solution for conservation of organs containing sodium chloride, potassium salt, magnesium salt, calcium salt, pH stabilizer and solvent which contains additionally, according to the invention, a local anesthetic, phenothiazine and purine derivatives, potassium and calcium gluconates as substitutes for calcium salts, magnesium sulphate as a substitute for magnesium salt, trihydroxymethylaminomethane as a pH stabilizer, and polyglucin as a solvent, in the following ratios of components, mM/l:
______________________________________ Sodium chloride 100.0-119.0
Potassium gluconate 12.0-17.0
Calcium gluconate 1.0-2.0
Magnesium sulphate 8.0-32.0
Trihydroxymethylaminomethane
2.0-3.0
Local anesthetic 0.33-1.66
Phenothiazine derivative
0.01-0.04
Purine derivative 1.0-2.0
Polyglucine the balance
______________________________________
The claimed solution extends considerably the conservation time of living organs up to 48 h.
BEST MODE OF CARRYING OUT THE INVENTION
The use of polyglucine for solvent increases radically the osmolarity of the solution (from 320 mOSm/l to 595 mOSm/l up) and prevents violent swelling of mitochondria and intracellular edema. The use of potassium and calcium salts in the form of gluconates and magnesium salt in the form of magnesium sulphate instead of chlorides permits reducing the content of chlorine ions in the solution since the toxic effect of the large number of these ions on the memb
REFERENCES:
patent: 4798824 (1989-01-01), Belzer et al.
patent: 4879283 (1989-11-01), Belzer et al.
patent: 4956272 (1990-09-01), Kakimoto et al.
patent: 4965185 (1990-10-01), Grischenko et al.
patent: 5110722 (1992-05-01), Brockbank et al.
patent: 5306711 (1994-04-01), Andrews
patent: 5328821 (1994-07-01), Fisher
patent: 5370989 (1994-12-01), Stern et al.
Berdyaev Sergei J.
Gretsky Svyatoslav O.
LandOfFree
Solution for conservation of living organs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solution for conservation of living organs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solution for conservation of living organs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-502677